ATG3 and non-small cell lung carcinoma: In the context of treating gefitinib-resistant NSCLC cell lines with a combination of gefitinib and YQCT, a significant increase in the protein levels of ATG3 and ATG12 in H1975 NSCLC cells after 48 h was observed, as compared with cells treated with gefitinib alone [93].